Improvement of Vascular Function by Acute and Chronic Treatment with the GPR30 Agonist G1 in Experimental Diabetes Mellitus

The G-protein coupled estrogen receptor 30 (GPR30) is a seven-transmembrane domain receptor that mediates rapid estrogen responses in a wide variety of cell types. This receptor is highly expressed in the cardiovascular system, and exerts vasodilatory effects. The objective of the present study was to investigate the effects of GPR30 on vascular responsiveness in diabetic ovariectomized (OVX) rats and elucidate the possible mechanism involved. The roles of GPR30 were evaluated in the thoracic aorta and cultured endothelial cells. The GPR30 agonist G1 induced a dose-dependent vasodilation in the thoracic aorta of the diabetic OVX rats, which was partially attenuated by the nitric oxide synthase (NOS) inhibitor, nitro-L-arginine methylester (L-NAME) and the GPR30-selective antagonist G15. Dose-dependent vasoconstrictive responses to phenylephrine were attenuated significantly in the rings of the thoracic aorta following the acute G1 administration in the diabetic OVX rats. This effect of G1 was abolished partially by L-NAME and G15. The acute administration of G1 increased significantly the eNOS activity and the concentration of NO in the endothelial cells exposed to high glucose. G1 treatment induced an enhanced endothelium-dependent relaxation to acetylcholine (Ach) in the diabetic OVX rats. Further examination revealed that G1 induced vasodilation in the diabetic OVX rats by increasing the phosphorylation of eNOS. These findings provide preliminary evidence that GPR30 activation leads to eNOS activation, as well as vasodilation, to a certain degree and has beneficial effects on vascular function in diabetic OVX rats.

[1]  M. Moskowitz,et al.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase , 1995, Nature.

[2]  P. Huang,et al.  Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. , 1999, American journal of physiology. Heart and circulatory physiology.

[3]  W. Sessa,et al.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt , 1999, Nature.

[4]  R. Busse,et al.  Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.

[5]  I. Meredith,et al.  Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes. , 2000, Journal of the American College of Cardiology.

[6]  P. Huang,et al.  Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. , 1999, Circulation research.

[7]  R. Busse,et al.  Signal transduction of eNOS activation. , 1999, Cardiovascular research.

[8]  R. Kumar,et al.  Insulinotropic and antidiabetic effects of 17β-estradiol and the GPR30 agonist G-1 on human pancreatic islets. , 2011, Endocrinology.

[9]  Hanjoong Jo,et al.  Compensatory Phosphorylation and Protein-Protein Interactions Revealed by Loss of Function and Gain of Function Mutants of Multiple Serine Phosphorylation Sites in Endothelial Nitric-oxide Synthase* , 2003, The Journal of Biological Chemistry.

[10]  E. Ferrannini,et al.  Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels. , 2005, European heart journal.

[11]  D. Clegg,et al.  Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. , 2009, Circulation research.

[12]  P. Huang.  Lessons learned from nitric oxide synthase knockout animals. , 2000, Seminars in perinatology.

[13]  D. Power,et al.  Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. , 2007, Journal of molecular and cellular cardiology.

[14]  Jianqiu Gu,et al.  L-arginine attenuates high glucose-accelerated senescence in human umbilical vein endothelial cells. , 2010, Diabetes research and clinical practice.

[15]  Tudor I. Oprea,et al.  GPR30: a novel therapeutic target in estrogen-related disease. , 2008, Trends in pharmacological sciences.

[16]  E. Prossnitz,et al.  Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. , 2011, Endocrinology.

[17]  N. Zhang,et al.  Neuroprotective effects of oestrogen against oxidative toxicity through activation of G‐protein‐coupled receptor 30 receptor , 2011, Clinical and experimental pharmacology & physiology.

[18]  X. Wang,et al.  Estrogen receptor alpha and G-protein coupled receptor 30 mediate the neuroprotective effects of 17β-estradiol in novel murine hippocampal cell models , 2010, Neuroscience.

[19]  E. Prossnitz,et al.  The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. , 2011, Vascular pharmacology.

[20]  K. Kamata,et al.  Gender differences in endothelial function in aortas from type 2 diabetic model mice. , 2009, Journal of pharmacological sciences.

[21]  C. Schalkwijk,et al.  [Vascular complications in diabetes mellitus: role of endothelial dysfunction]. , 1996, Nederlands tijdschrift voor geneeskunde.

[22]  C. Sobey,et al.  Endothelium-dependent relaxation by G protein-coupled receptor 30 agonists in rat carotid arteries. , 2010, American journal of physiology. Heart and circulatory physiology.

[23]  E. Prossnitz,et al.  The G-protein-coupled estrogen receptor GPER in health and disease , 2011, Nature Reviews Endocrinology.

[24]  Paul L Huang.  eNOS, metabolic syndrome and cardiovascular disease , 2009, Trends in Endocrinology & Metabolism.

[25]  E. Prossnitz,et al.  Dilation of Epicardial Coronary Arteries by the G Protein-Coupled Estrogen Receptor Agonists G-1 and ICI 182,780 , 2010, Pharmacology.

[26]  D. Atochin,et al.  Endothelial nitric oxide synthase transgenic models of endothelial dysfunction , 2010, Pflügers Archiv - European Journal of Physiology.

[27]  R. Gerszten,et al.  Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. , 2004, American journal of physiology. Cell physiology.

[28]  Paul L Huang.  Unraveling the links between diabetes, obesity, and cardiovascular disease. , 2005, Circulation research.

[29]  Tudor I. Oprea,et al.  Virtual and biomolecular screening converge on a selective agonist for GPR30 , 2006, Nature chemical biology.

[30]  E. Prossnitz,et al.  Vasodilation in Response to the GPR30 Agonist G-1 is Not Different From Estradiol in the mRen2.Lewis Female Rat , 2011, Journal of cardiovascular pharmacology.

[31]  W. Cao,et al.  Down-regulation of NR2B receptors partially contributes to analgesic effects of Gentiopicroside in persistent inflammatory pain , 2008, Neuropharmacology.

[32]  A. Salehi,et al.  Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice , 2010, Molecular and Cellular Endocrinology.

[33]  E. Prossnitz,et al.  Deletion of G Protein–Coupled Estrogen Receptor Increases Endothelial Vasoconstriction , 2012, Hypertension.

[34]  Tudor I. Oprea,et al.  Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  K. Tracey,et al.  Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.

[36]  Steven P Jones,et al.  Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. , 1999, American journal of physiology. Heart and circulatory physiology.

[37]  Tudor I. Oprea,et al.  In vivo Effects of a GPR30 Antagonist , 2009, Nature chemical biology.